BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/96/0.1/20.12.24

BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/96/0.1/20.12.24 Share Price

DE000VD3R5L8

Real-time Boerse Frankfurt Warrants 05:23:37 02/07/2024 pm IST
0.52 ^EUR	-7.14%

Current month	-18.84%
1 month	+30.23%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart EDWARDS LIFESCIENCES CORPORATION

Chart BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/96/0.1/20.12.24

Latest news about EDWARDS LIFESCIENCES CORPORATION

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating	05:41pm	MT
Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing	21/06	MT
Edwards Lifesciences Corporation Announces Executive Changes	18/06	CI
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75	17/06	MT

More news

Quotes 5-day view

Date	Price	Change
02/24/02	0.52	-7.14%
01/24/01	0.56	-18.84%
28/24/28	0.69	-2.82%
27/24/27	0.71	+18.33%
26/24/26	0.6	+9.09%

Real-time Boerse Frankfurt Warrants

Last update July 02, 2024 at 05:23 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	EDWARDS LIFESCIENCES CORPORATION
Issuer	Vontobel
WKN	VD3R5L
ISIN	DE000VD3R5L8
Date issued	09/04/2024
Strike	96 $
Maturity	20/12/2024 (171 Days)
Parity	10 : 1
Emission price	0.9 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.94 €
Lowest since issue	0.4 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	24.06x
Moneyness	1.452
Difference Strike	5.75 $
Difference Strike %	+5.99%
Spread	0.02 €
Spread %	3.64%
Intrinsic value	4.044
Present value	-3.503879

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

More about the company